The present study was performed in the framework of an integrated care program run according to the premises of treat-to-target and adhering to the recommendations of centers of excellence in the treatment of RA.[24] Data from our cohort (400 Colombian patients diagnosed with RA and receiving treatment with anti-TNF alpha drugs) enabled us to establish that a positive RF titer could predict a lower rate of remission and severe disability. The gene discussed is TNF; the disease is rheumatoid arthritis.